Compare Abbott Laboratories (ABT) vs FirstEnergy Corp. (FE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs FirstEnergy Corp. — how do they compare? Abbott Laboratories trades at $109.55 (market cap $187.95B), while FirstEnergy Corp. trades at $46.86 (market cap $27.06B). The key difference: Abbott Laboratories is far larger — about 6.9× FirstEnergy Corp.'s market cap, and FirstEnergy Corp. pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| ABT | FE | |
|---|---|---|
Market Cap | $187.95B | $27.06B |
Sector | Health | Utilities |
52-Week High | $136.62 | $51.91 |
52-Week Low | $82.57 | $42.83 |
Enterprise Value | $214.96B | $55.98B |
Dividend Yield | 2.32% | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
FirstEnergy (FE) trades at $47.47, up 0.2% today, with a bearish technical signal from indicators like the 6-day RSI at 11.10 and ADX signaling strong trend strength. The company reported Q2 2026 EPS of $0.50, slightly missing expectations, but revenue growth is supported by data center demand and a $36 billion grid investment plan. Analyst consensus is a Buy with a $52.67 price target, though technicals suggest near-term pressure.
The outlook is mixed: strong fundamentals with rising revenue and stable margins offer long-term value, but technical bearishness and high debt levels pose risks. Investment opportunity lies in grid expansion and data center growth, while risks include execution challenges and interest rate sensitivity. The stock presents a defensive play with growth potential amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →
